
Welcome to SEAAIS 2025



Dear Members, Guests et al:

Greetings. After a hiatus of many years, we are returning to the Greenbrier. It is the most fitting venue to celebrate the 80th anniversary of the SEAAIS. Visitors have been coming to the White Sulphur Springs area since before the Revolutionary War to avail themselves of the healing power of the warm springs. Indeed, the old springhouse cupola is prominent in the area near the outdoor swimming pool and tennis courts. The springhouse motif is seen on resort sportswear, and carpeting throughout the hotel.

At the Greenbrier, there is something for everyone. A variable plethora of activities awaits, including horseback riding, archery, fly fishing, white water rafting, skeet shooting, Jeep 4 x 4 off-roading and a casino along with more mundane activities, such as bowling croquet, Tennis, golf, multiple fitness centers, including an indoor lap pool dating back to 1912. Golfers will appreciate the three famous former pros, Sam Snead, Tom Watson, Lee Trevino, whose pictures and artifacts adorn the clubhouse. There are three courses from which to choose including the Old White course containing what Tom Watson described as the most beautiful opening tee in all of golf.

The hotel is not only about comfort and leisure, it played a very important role in our national defense during the tumultuous years of the Cold War. A bunker was secretly constructed around 1959-60 for the President, Vice President and Congress as a fall out shelter in the event of nuclear attack on Washington DC. It remained in this capacity over 30 years before being revealed. Today you may tour the bunker and appreciate, not only the austere conditions, but the plans to keep government functioning in the event of attack. Quite fascinating; I highly recommend it.

Guests at the Greenbrier will be delighted with the attention to almost every conceivable detail. The extra touches like afternoon tea service on the first floor lobby and nightly movies in the lower floor theater are delightful. There is a non-denominational chapel for Sunday worship at 9 AM across from the croquet court. Multiple restaurants, including the main dining room, Sam Sneads, Prime 44 West, The Forum, and Slammin' Sammy's span a wide culinary range.

Nearby the Greenbrier about 9 miles down Highway 60 is the lovely town of Lewisburg, voted coolest small town in America. This hamlet features a historic downtown, quaint shopping, beautiful old homes, and fine restaurants, including an authentic German beer garden with appropriate Teutonic dishes. Nearby is the Greenbrier River Trail along an old railroad right away. It is great for joggers, walkers, and bicyclists and features old railway machinery and a tunnel.

Respectfully submitted,
Jack Eades, MD, FAAAAI, FACAAI
Site selection committee chairperson.

SEAAIS 2025 Poster Sessions (Non-CME)



The Poster Session is designed to provide an opportunity for researchers, clinicians, and industry partners to share innovative findings, case reports, research data, or new product developments relevant to the field of allergy, asthma, and immunology. Posters will be on display at the back of the Exhibitor Hall (Colonial Hall). The poster schedule is October 24th: 7:30 – 8 AM EST, 9:45 – 10:25 AM EST, and 12:15 – 1 PM EST and October 25th: 7:30 – 8 AM EST, 10:15 – 10:45 AM EST, and 12:25 – 1:05 PM EST

Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Presenting author: Kushal Bhatt, PharmD, MBA, Cogent Biosciences, Waltham, MA

Authors: Frank Siebenhaar, MD¹, Nicole Sparling, MA², Cem Akin, MD³, Jennifer Nicoloro-SantaBarbara, PhD⁴, Jenna Zhang, PhD⁵, Rachael Easton, MD, PhD⁵, Michelle Lim-Watson, PhD, MPH, MBA⁵, Emily Ruzich, PhD², Jean Paty, PhD²

Epinephrine Delivered via Sublingual Film (Anaphylm™) Elicits Rapid and Consistent Pharmacokinetic and Pharmacodynamic Responses

Presenting author: Nils Confer, PhD., Aquestive Therapeutics, Inc.

Authors: Carl Kraus, MD¹, Nils Confer, PhD¹, David Golden, MD², David Bernstein, MD³, Matthew Greenhawt, MD⁴

¹Aquestive Therapeutics, Inc, ²Medstar Franklin Square Hospital, Baltimore, MD, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ⁴Asthma and Allergy Foundation of America, Arlington, VA

Phase 1 Evaluation of Anaphylm™ Sublingual Film: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Pediatric Patients at High Risk for Allergic Reactions

Presenting author: Nils Confer, PhD., Aquestive Therapeutics, Inc.

Authors: David Golden, MD¹, Matthew Greenhawt, MD², Nils Confer, PhD³, Carl Kraus, MD³

¹Medstar Franklin Square Hospital, Baltimore, MD, ²Asthma and Allergy Foundation of America, Arlington, VA, ³Aquestive Therapeutics, Inc

SEAAIS 2025 Poster Sessions (Non-CME) Continued



Burden of Treatment for Pediatric Patients (Aged Less Than 12 Years) With Hereditary Angioedema and Their Caregivers

Presenting author: Mark Freebery, PharmD (BioCryst), on behalf of the authors

Authors: Patricia Stewart¹, Tamara Ray², Diane Ramsey-Paige², Daniel Petroni², Clare Murphy³, Nicole Garberg³

¹Mississippi Asthma and Allergy Clinic PA, Jackson, MS, USA; ²BioCryst Pharmaceuticals, Durham, NC, USA; ³KJT Group, Inc., Rochester, NY, USA

COMFORT Toddlers: phase 3 supplemental safety study of epicutaneous immunotherapy in 1-through-3-year-old peanut-allergic toddlers.

Presenting author: Maribeth Kowalski, PharmD, DBV Technologies

Authors: Todd D. Green, MD,^{1,2} Julie Wang, MD,³ Sara Anvari, MD, MSc,⁴ Matthew Greenhawt, MD,⁵ Douglas P. Mack, MD,⁶ Sarita Chainani, MS,¹ Karine Rutault, PhD,¹ Hugh A. Sampson, MD³

¹DBV Technologies SA, Châtillon, France; ²UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ³Department of Pediatrics, Serena & John Liew Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁴Division of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA;

⁵Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA; ⁶McMaster University, Hamilton, ON, Canada

SEAAIS 2025 Poster Sessions (Non-CME) Continued



Being Attack-Free With Garadacimab Improves Quality Of Life In Patients With Hereditary Angioedema

Presenting author: Michael Maahs, PhD, CSL Behring, on behalf of the authors

Authors: F. Ida Hsu¹, William R. Lumry², Emel Aygören-Pürsün³, Julia Braverman⁴, John-Philip Lawo⁵, Maressa Pollen⁴, Chiara Nenci⁶, Timothy J. Craig⁷

¹North Haven Medical Center, Yale New Haven Health, North Haven, CT, USA

²AARA Research Center, Dallas, TX, USA

³Klinikum der Johann Wolfgang-Goethe Universität, Klinik für Kinder- und Jugendmedizin, Frankfurt, Germany

⁴CSL Behring, King of Prussia, PA, USA

⁵CSL Behring Innovation GmbH, Marburg, Germany

⁶CSL Behring AG, Bern, Switzerland

⁷Allergy, Asthma and Immunology, Department of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA

Clinical Evidence With Garadacimab Demonstrates No Impact On hemostasis

Presenting author: Bill Maltas, PharmD, CSL Behring, on behalf of the authors

Authors: Danny M. Cohn¹, Henriette Farkas², Marc Riedl³, Harsha Shetty⁴, Subhajit Ghosh⁵, John-Philip Lawo⁵, Maressa Pollen⁴, H. Henry Li⁶

¹Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

²Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary

³University of California San Diego, San Diego, CA, USA

⁴CSL Behring, King of Prussia, PA, USA

⁵CSL Innovation GmbH, Marburg, Germany

⁶Institute for Asthma and Allergy, Chevy Chase, MD, USA

SEAAIS 2025 Poster Sessions (Non-CME) Continued



Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study

Presenting author: Amy Monpara, PharmD, Blueprint Medicines

Authors: Hanneke Oude Elberink,¹ Cem Akin,² Mariana Castells,³ Jason Gotlib,⁴ Jens Panse,^{5,6} Deepti H. Radia,⁷ Frank Siebenhaar,^{8,9} Tsewang Tashi,¹⁰ Cristina Bulai Livideanu,¹¹ Karin Hartmann,^{12,13,14} Sigurd Broesby-Olsen,¹⁵ Tracy I. George,^{10,16} Vito Sabato,¹⁷ Paul Van Daele,¹⁸ Sonia Cerquozzi,¹⁹ Ingunn Dybedal,²⁰ Joseph Jurcic,²¹ Stéphane Barete,²² Andreas Reiter,²³ Thanai Pongdee,²⁴ Ruchi Desai,²⁵ Philippe Schafhausen,²⁶ Celalettin Ustun,²⁷ Prithviraj Bose,²⁸ Peter Vadas,²⁹ Massimo Triggiani,³⁰ Patrizia Bonadonna,³¹ Daniel J. DeAngelo,³² Lindsay Rein,³³ Pankit Vachhani,³⁴ Ilda Bidollari,³⁵ Hui-Min Lin,³⁵ Janet Hong,³⁵ Benjamin Lampson,³⁵ Ashley Doyle,³⁵ Ivan Alvarez-Twose³⁶

¹Department of Allergology, University Medical Center, Groningen Research Institute Asthma and COPD, University of Groningen, Groningen, The Netherlands; ²University of Michigan, Ann Arbor, MI, USA; ³Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ⁴Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA, USA; ⁵Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital Aachen, Medical Faculty, RWTH Aachen University, Aachen, Germany; ⁶Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany; ⁷Guy's & St Thomas' NHS Foundation Trust, London, UK; ⁸Institute of Allergology, Charité–Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ⁹Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; ¹⁰Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; ¹¹Unit of Dermatology, Reference Centre for Mastocytosis (CEREMAST) Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France; ¹²Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; ¹³Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; ¹⁴Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland; ¹⁵Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark; ¹⁶ARUP Laboratories, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA; ¹⁷Department of Immunology, Allergology and Rheumatology, University of Antwerp, and Antwerp University Hospital, Antwerp, Belgium; ¹⁸Department of Internal Medicine and Immunology, Erasmus Medical Center, Rotterdam, Netherlands; ¹⁹Department of Medicine, University of Calgary, Calgary, AB, Canada; ²⁰Department of Hematology and Pharmacology, Oslo University Hospital, Oslo, Norway; ²¹Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA; ²²Department of Dermatology, Expert Center of Mastocytosis (CEREMAST), Toulouse University Hospital, Toulouse, France; ²³Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; ²⁴Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA; ²⁵Division of Hematology/Oncology and Palliative Care, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; ²⁶Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²⁷Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Section of Bone Marrow Transplantation and Cellular Therapy, Rush Medical College, Chicago, IL, USA; ²⁸Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²⁹Department of Medicine, Division of Clinical Immunology and Allergy, St. Michael's Hospital University of Toronto, Toronto, Ontario, Canada; ³⁰Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy; ³¹Allergy Unit and Asthma Center, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; ³²Dana-Farber Cancer Institute, Boston, MA, USA; ³³Department of Medicine, Duke University, School of medicine, Durham, NC, USA; ³⁴Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; ³⁵Blueprint Medicines Corporation, Cambridge, MA, USA; ³⁶Institute of Mastocytosis Studies of Castilla-La Mancha, Virgen del Valle Hospital, Toledo, Spain.

SEAAIS 2025 Poster Sessions (Non-CME) Continued



Patient Characteristics and Social Determinants of Health Influence Adherence to Biologic Therapy for Asthma

Presenting author: Kristin O'Rear, PharmD, US Medical Affairs – Anti-Infectives & Respiratory (AIR) Virginia/Kentucky

Authors: Diego J Maselli, MD¹, Justin Kwiatak, PharmD², Arijita Deb, PhD³, Guillaume Germain, MSc⁴, François Laliberté, MSc⁴, Malena Mahendran, MSc⁴, Patrick Gravelle, PhD⁴, Annalise Hilts, BSc⁴, Rohit Katial, MD⁵

¹Division of Pulmonary Disease & Critical Care Medicine, Department of Medicine, University of Texas Health at San Antonio, San Antonio, TX, USA; ²US Medical Affairs, GSK, Collegeville, PA, USA; ³Global Real-World Evidence & Health Outcomes Research, GSK, Collegeville, PA, USA; ⁴Groupe d'analyse SRI, Montréal, QC, Canada; ⁵Division of Allergy & Clinical Immunology, Department of Medicine, National Jewish Health and University of Colorado, Denver, CO, USA

Twice-yearly Depemokimab Reduces Exacerbations Versus Placebo in Patients with Asthma Across Age of Onset/Duration Subgroups: Phase III SWIFT-1/2 studies

Presenting author: Kristin O'Rear, PharmD, US Medical Affairs – Anti-Infectives & Respiratory (AIR) Virginia/Kentucky

Authors: David J Jackson, FRCP, MSc, PhD¹, Florence Schleich, MD², Diana Jarreta, BSChem³, Chang-Qing Zhu, PhD⁴, Peter Howarth, MD⁵, Michael E Wechsler, MD⁶

¹Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, King's College London, London, UK; ²University of Liège, Liège, Belgium; ³Clinical Sciences, GSK, Madrid, Spain; ⁴Biostatistics, GSK, London, UK; ⁵Global Medical Affairs, Specialty Care, GSK, London, UK; ⁶Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA

Real-World Persistence to Biologic Therapies and its Impact on Outcomes in Patients with Asthma

Presenting author: Kristin O'Rear, PharmD, US Medical Affairs – Anti-Infectives & Respiratory (AIR) Virginia/Kentucky

Authors: Justin Kwiatak, Pharm D¹, Arijita Deb, PhD², Guillaume Germain, MSc³, Malena Mahendran, MSc³, Patrick Gravelle, PhD³, Annalise Hilts, BSc³, Susannah Ripley, PhD³, François Laliberté, MSc³

¹US Medical Affairs, GSK, Collegeville, PA, USA; ²Global Real-World Evidence & Health Outcomes Research, GSK, Collegeville, PA, USA; ³Groupe d'analyse, Ltée, Montreal, QC, Canada

SEAAIS 2025 Poster Sessions (Non-CME) Continued



Real-World Hereditary Angioedema Attack Rates Before and After Berotralstat Initiation Among Adolescents

Presenting author: Jesse Quintiliani, PharmD, (BioCryst), on behalf of the authors

Authors: William R. Lumry¹, Mark Davis-Lorton², Sean D. MacKnight³, François Laliberté³, Cristina Martinez³, Patrick Gillard⁴, Raffi Tachdjian⁵

¹Allergy and Asthma Research Associates, Dallas, TX, USA; ²ENT and Allergy Associates, Tarrytown, NY, USA; ³Groupe d'Analyse, Ltée, Montreal, QC, Canada; ⁴BioCryst Pharmaceuticals, Durham, NC, USA; ⁵Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA

Bezuclastinib Expanded Access Program (EAP) for Patients with Systemic Mastocytosis (SM)

Presenting author: Stefanie Schwartz, PharmD, Cogent Biosciences, Waltham, MA

Authors: Lindsay Rein¹, Ali Malinowski², Jenni Nicoloro SantaBarbara³, Ravi Jalluri², LouAnn Cable², Karyn Bouhana², Michelle Crow², Ben Exter², Jay Chatfield², Dana Martin², Rachael Easton², Cem Akin⁴

¹Duke University, Durham, NC, USA; ²Cogent Biosciences, Inc. Waltham, MA, USA; ³Brigham and Women's Hospital, Boston, MA, USA; ⁴University of Michigan, Ann Arbor, MI, USA
